The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 361:1610-1611 October 15, 2009 Number 16
NextNext

HPV Vaccination

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Kahn, J. A.
-PubMed Citation
To the Editor: In her review of human papillomavirus (HPV) vaccination (July 16 issue),1 Kahn neglects to discuss one key "area of uncertainty," namely, the extent to which other high-risk oncogenic HPV types may rapidly occupy the epidemiologic niche vacated by vaccine-targeted HPV types 16 and 18. If this rapid occupation occurs, the large expenditure of health care dollars for widespread HPV vaccination would be rendered futile.


Steven Leiner, N.P.
Mission Neighborhood Health Center
San Francisco, CA
steven.leiner@gmail.com

  1. Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med 2009;361:271-278. [Free Full Text]
 
The author replies: It is not likely that the prevalence of HPV types not targeted by vaccines will increase to fill an . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.